GETI.B

210.7

-1.08%↓

CAMX

597.5

+2.4%↑

BIOAB

317.4

+3.52%↑

VITR

130

-1.59%↓

AMBEA

141.9

+2.09%↑

GETI.B

210.7

-1.08%↓

CAMX

597.5

+2.4%↑

BIOAB

317.4

+3.52%↑

VITR

130

-1.59%↓

AMBEA

141.9

+2.09%↑

GETI.B

210.7

-1.08%↓

CAMX

597.5

+2.4%↑

BIOAB

317.4

+3.52%↑

VITR

130

-1.59%↓

AMBEA

141.9

+2.09%↑

GETI.B

210.7

-1.08%↓

CAMX

597.5

+2.4%↑

BIOAB

317.4

+3.52%↑

VITR

130

-1.59%↓

AMBEA

141.9

+2.09%↑

GETI.B

210.7

-1.08%↓

CAMX

597.5

+2.4%↑

BIOAB

317.4

+3.52%↑

VITR

130

-1.59%↓

AMBEA

141.9

+2.09%↑

Search

Elekta AB

Open

56.3 0.45

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

55.65

Max

56.55

Schlüsselkennzahlen

By Trading Economics

Einkommen

94M

230M

Verkäufe

424M

4.1B

KGV

Branchendurchschnitt

74.079

76.798

EPS

0.64

Dividendenrendite

4.32

Gewinnspanne

5.651

Angestellte

4,484

EBITDA

20M

529M

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

4.32%

2.37%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

4.9B

22B

Vorheriger Eröffnungskurs

55.85

Vorheriger Schlusskurs

56.3

Elekta AB Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

18. Dez. 2025, 23:54 UTC

Heiße Aktien

Stocks to Watch: Nike, Cassava Sciences, KB Home

18. Dez. 2025, 23:51 UTC

Ergebnisse

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18. Dez. 2025, 23:39 UTC

Wichtige Markttreiber

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18. Dez. 2025, 22:57 UTC

Akquisitionen, Fusionen, Übernahmen

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18. Dez. 2025, 21:40 UTC

Ergebnisse

Nike Sales Tick Up, But China Weakness Persists

18. Dez. 2025, 23:45 UTC

Market Talk

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18. Dez. 2025, 23:37 UTC

Market Talk
Ergebnisse

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18. Dez. 2025, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18. Dez. 2025, 23:03 UTC

Akquisitionen, Fusionen, Übernahmen

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18. Dez. 2025, 23:02 UTC

Akquisitionen, Fusionen, Übernahmen

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18. Dez. 2025, 23:00 UTC

Akquisitionen, Fusionen, Übernahmen

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18. Dez. 2025, 22:59 UTC

Akquisitionen, Fusionen, Übernahmen

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18. Dez. 2025, 22:58 UTC

Akquisitionen, Fusionen, Übernahmen

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18. Dez. 2025, 22:57 UTC

Akquisitionen, Fusionen, Übernahmen

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18. Dez. 2025, 22:56 UTC

Akquisitionen, Fusionen, Übernahmen

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18. Dez. 2025, 22:55 UTC

Ergebnisse

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18. Dez. 2025, 21:59 UTC

Ergebnisse

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18. Dez. 2025, 21:50 UTC

Market Talk
Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

18. Dez. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18. Dez. 2025, 21:35 UTC

Ergebnisse

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18. Dez. 2025, 21:31 UTC

Ergebnisse

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18. Dez. 2025, 21:15 UTC

Ergebnisse

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18. Dez. 2025, 21:15 UTC

Ergebnisse

Nike 2Q Greater China Rev Down 17% >NKE

18. Dez. 2025, 21:15 UTC

Ergebnisse

Nike 2Q EPS 53c >NKE

18. Dez. 2025, 21:15 UTC

Ergebnisse

Nike 2Q Apparel Rev $3.91B >NKE

18. Dez. 2025, 21:15 UTC

Ergebnisse

Nike 2Q Equipment Rev $550M >NKE

18. Dez. 2025, 21:15 UTC

Ergebnisse

Nike 2Q N Amer Rev $5.63B >NKE

18. Dez. 2025, 21:15 UTC

Ergebnisse

Nike 2Q Footwear Rev $7.66B >NKE

18. Dez. 2025, 21:15 UTC

Ergebnisse

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

18. Dez. 2025, 21:15 UTC

Ergebnisse

Nike 2Q Greater China Rev $1.42B >NKE

Peer-Vergleich

Kursveränderung

Elekta AB Prognose

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Elekta AB

Elekta AB (publ), a medical technology company, engages in the provision of clinical solutions for treating cancer and brain disorders worldwide. The company offers radiation therapy products, including Elekta Unity for real-time MR visualization; Elekta Versa HD, a brain metastases solution; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; and quality assurance, and treatment and motion management solutions. It also provides stereotactic radiosurgery products, such as Elekta Esprit; Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Leksell GammaPlan, a treatment planning and management software. In addition, the company offers Elekta ONE, a software suite of multiple Elekta solutions. Further, it provides brachytherapy products, including Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Elekta Xoft Axxent, and electronic brachytherapy systems; Elekta Geneva, an applicator for cervical cancer patients; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Venezia applicator that enables the oncologist to treat locally advanced cervical cancer. Additionally, the company offers neurosurgery products, such as Leksell Vantage Stereotactic System for intracranial neurosurgery. Furthermore, it provides Elekta Kaiku for personalized cancer care; and veterinary radiation therapy solutions. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.
help-icon Live chat